Defence Therapeutics Inc. (OTCMKTS:DTCFF – Get Free Report) shares were down 8.6% during trading on Friday . The company traded as low as $0.3655 and last traded at $0.3655. Approximately 26,400 shares traded hands during mid-day trading, an increase of 258% from the average daily volume of 7,375 shares. The stock had previously closed at $0.40.
Defence Therapeutics Price Performance
The stock has a 50 day moving average price of $0.39 and a 200 day moving average price of $0.46.
Defence Therapeutics Company Profile
Defence Therapeutics is a clinical-stage biotechnology company focused on the development of innovative immuno-oncology therapies. Headquartered in Montreal, Canada, the company leverages its proprietary Oncoprex platform to deliver targeted immunomodulatory treatments designed to stimulate the body’s immune response against solid tumors. Its research and development efforts center on novel approaches that aim to enhance efficacy while minimizing systemic side effects commonly associated with conventional cancer therapies.
The Oncoprex platform employs a unique vectorization technology to transport immunotherapeutic agents directly into the tumor microenvironment.
Recommended Stories
- Five stocks we like better than Defence Therapeutics
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Receive News & Ratings for Defence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Defence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
